Literature DB >> 3409269

Vasopressin and 1-deamino-8-D-arginine-vasopressin (DDAVP) reduce elevated plasma catecholamine levels in rats with hypothalamic deafferentation.

R Kvetnanský1, B Lichardus, D Jezová, Z Oprsalová, G B Makara.   

Abstract

1. Anterolateral cut (ALC) of the medial basal hypothalamus (MBH) in rats produces an elevation of plasma catecholamine levels, especially of norepinephrine (NE), in unstressed animals and a more pronounced rise of plasma NE levels in response to immobilization (IMO). Animals with ALC have a destroyed corresponding vasopressin (AVP) and other peptides containing innervation of the median eminence and the posterior pituitary, resulting in the prevention of increased AVP secretion during the early intervals of IMO. 2. The administration of AVP (Pitressin, 7 days, 1 IU per rat i.m.) or of 1-deamino-8-D-arginine-vasopressin (DDAVP), an AVP analogue without pressoric activity, taken in drinking water (about 100 micrograms per day) was almost equally potent in decreasing the elevated water consumption and plasma NE levels in unstressed rats with ALC. However, the stress-induced potentiation of plasma NE levels in rats with ALC was not influenced by AVP substitution and only partly reduced by DDAVP in the late IMO intervals. 3. The lack of circulating vasopressin is the main factor in the mechanism of increased activity of the sympathoadrenal system induced by ALC in unstressed rats. 4. The regulation of sympathoadrenal activity by vasopressin and DDAVP in rats with ALC seems to be mediated predominantly by V2-subtype receptors. 5. In stressed rats with ALC the potentiation of plasma NE levels was not reduced after AVP or DDAVP administration, suggesting that some addition regulatory mechanisms were involved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409269     DOI: 10.1007/bf00711248

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  22 in total

1.  Adrenal and urinary catecholamines in rats during adaptation to repeated immobilization stress.

Authors:  R Kvetnansky; L Mikulaj
Journal:  Endocrinology       Date:  1970-10       Impact factor: 4.736

2.  Increased biosynthesis of cardiac norepinephrine after hypophysectomy.

Authors:  L Landsberg; J De Champlain; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1969-01       Impact factor: 4.030

Review 3.  Arginine vasopressin (AVP) and AVP-like immunoreactivity in peripheral tissues.

Authors:  J A Clements; J W Funder
Journal:  Endocr Rev       Date:  1986-11       Impact factor: 19.871

4.  Absorption of intragastrically administered DDAVP in conscious dogs.

Authors:  S Lundin; H Vilhardt
Journal:  Life Sci       Date:  1986-02-24       Impact factor: 5.037

5.  Reevaluation of the pituitary-adrenal response to ether in rats with various cuts around the medial basal hypothalamus.

Authors:  G B Makara; E Stark; M Polkovits
Journal:  Neuroendocrinology       Date:  1980       Impact factor: 4.914

6.  Oxytocin inhibits ACTH and peripheral catecholamine secretion in the urethane-anesthetized rat.

Authors:  D M Gibbs
Journal:  Regul Pept       Date:  1986-04

7.  Cardiovascular, sympathetic, and renin-angiotensin system responses to hemorrhage in vasopressin-deficient rats.

Authors:  R L Zerbe; G Feuerstein; D K Meyer; I J Kopin
Journal:  Endocrinology       Date:  1982-08       Impact factor: 4.736

8.  Contrasting effects of vasopressin on baroreflex inhibition of lumbar sympathetic nerve activity.

Authors:  F M Sharabi; G B Guo; F M Abboud; M D Thames; P G Schmid
Journal:  Am J Physiol       Date:  1985-11

9.  A vasopressin-like peptide in the mammalian sympathetic nervous system.

Authors:  M R Hanley; H P Benton; S L Lightman; K Todd; E A Bone; P Fretten; S Palmer; C J Kirk; R H Michell
Journal:  Nature       Date:  1984 May 17-23       Impact factor: 49.962

10.  Central vasopressin in the modulation of catecholamine release in conscious rats.

Authors:  K A King; G Mackie; C C Pang; R A Wall
Journal:  Can J Physiol Pharmacol       Date:  1985-12       Impact factor: 2.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.